Otsuka drops Alzheimer's agitation candidate

The decision was made after the drug candidate failed to show a statistically significant effect compared to placebo in a phase III trial.
Photo: Henning Kaiser/AP/Ritzau Scanpix
Photo: Henning Kaiser/AP/Ritzau Scanpix

Japanese pharmaceutical company Otsuka Pharmaceutical and its US subsidiary have decided to stop the development of the drug candidate AVP-786 as a treatment for anger outbursts - also known as agitation - associated with dementia in Alzheimer’s patients. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Foto: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading